BRD2 and gastric cancer: First and foremost, it is essential to clarify whether NAT adversely affects the short-term postoperative outcomes of elderly patients who have difficulty tolerating NAT, although multiple published clinical trials have already demonstrated that NAT does not adversely affect the short-term postoperative outcomes of gastric cancer patients [4, 20–23].